CordenPharma, a leading global Contract Development and Manufacturing Organisation (CDMO), has acquired AmbioPharm, a US-headquartered peptide API CDMO.
With its two sites in South Carolina (USA) and Shanghai (China), AmbioPharm adds differentiated peptide manufacturing capabilities to CordenPharma’s existing Peptides Platform and expertise. Once combined, these will include advanced linear and fragment-based peptide approaches supported by flexible Solid-Phase Peptide Synthesis (SPPS), Liquid-Phase Peptide Synthesis (LPPS), and hybrid synthesis, as well as CordenPharma’s Tag-Assisted Peptide Synthesis (TAPS). Following closing, the acquisition will give customers flexible options to match their specific manufacturing requirements for complex, long and high-purity peptide APIs.
AmbioPharm employs approximately 400 people across its two sites. The acquisition builds on CordenPharma’s global facility network of 11 sites in Europe and North America by expanding its US peptide manufacturing capacity and bringing Shanghai-based peptide supply into its operational footprint.
As CordenPharma’s second US peptide facility, the acquisition of AmbioPharm’s North Augusta, SC site will add significant capacity focused on purification and lyophilisation of peptide APIs. The acquisition will complement existing capabilities in CordenPharma Colorado (US), allowing CordenPharma to deliver fully US-based peptide API supply options to meet customer needs for large-scale commercial peptide projects.
At AmbioPharm’s Shanghai campus, CordenPharma will leverage the new state-of-the-art peptide manufacturing facility to support clinical and commercial global peptide supply with significant upstream capacity across SPPS, LPPS and hybrid synthesis, as well as selected downstream capabilities.
By integrating the North Augusta and Shanghai sites, CordenPharma expands its global Peptides Platform across three continents, offering customers end-to-end peptide development and manufacturing support.
Since CordenPharma was acquired by Astorg in 2022, the company has continued to expand its global peptide platform through strategic investments and expanded manufacturing capacity. As part of the transaction, AmbioPharm’s shareholders will reinvest into the combined business. This reinvestment reflects shareholders’ confidence in the capabilities and long-term growth potential of the expanded Peptides Platform. The transaction remains subject to customary closing conditions. Financial terms have not been disclosed.
